Uli Stilz is Vice President of Innovation and Outreach at Novo Nordisk A/S based in Boston. In this role he is responsible for connecting Novo Nordisk R&D to the Boston science and entrepreneurial community with a special emphasis on disruptive “blue sky science” to enable potential future first-in-class pipeline assets and enabling capabilities and technologies. Furthermore he oversees Novo Nordisk’s Open Innovation programs.

Uli Stilz graduated with a Master degree in Organic Chemistry from ETH Zürich. He then moved to the Max-Planck-Institute of Biochemistry in Martinsried, where he received his PhD in 1990.

After postdoctoral studies at the California Institute of Technology he joined Hoechst AG were he held various positions before he was appointed Vice President of the newly established innovation unit within the Diabetes Division at Sanofi in 2010. Over a period of 20 years he contributed to more than 50 preclinical/clinical drug candidates.

In 2014 he joined Novo Nordisk A/S in Copenhagen and relocated to Boston in 2019 to assume his current role as Vice President Innovation and Outreach. Uli Stilz was appointed adjunct professor at the University of Frankfurt in 2012. He serves on various Editorial Boards for international peer-reviewed journals, is member of Scientific Advisory Boards in Europe and North America, and has represented Novo Nordisk A/S at trade organisations (EFPIA). Between 2012 and 2014 he was President of the European Federation for Medicinal Chemistry.